Medite Cancer Diagnostics

Medite Cancer Diagnostics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medite Cancer Diagnostics (MDIT) as of Nov 1, 2026 is -6.19 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.45 M USD — a change of 327.57% (lower).

EBITDA

-6.19 MUSD

YoY

327.57%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medite Cancer Diagnostics is 2017 -6.19 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medite Cancer Diagnostics was 2016 -1.45 M USD. It decreases by 327.57% lower compared to the previous year.

The Medite Cancer Diagnostics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2014
-224,000.00 USD
Jan 1, 2015
-422,000.00 USD
Jan 1, 2016
-1.45 M USD
Jan 1, 2017
-6.19 M USD
The Medite Cancer Diagnostics EBITDA history
YEAREBITDAYoY
-6.19 MUSD+327.57%
-1.45 MUSD+242.89%
-422,000.00USD+88.39%
-224,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medite Cancer Diagnostics Stock analysis

What does Medite Cancer Diagnostics do? Medite Cancer Diagnostics Inc is a company that specializes in the development and marketing of medical products for the diagnosis and treatment of cancer. The company was founded in 1995 by Arndt G. Schüttler and is headquartered in Orlando, Florida. Medite Cancer Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medite Cancer Diagnostics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medite Cancer Diagnostics is -6.19 M USD in 2017.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medite Cancer Diagnostics changed from -1.45 M USD to -6.19 M USD, representing a 327.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Medite Cancer Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Medite Cancer Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Medite Cancer Diagnostics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Medite Cancer Diagnostics